Morphological and Functional Evaluation of Irvine-Gass Syndrome

Irvine Gass Syndrome Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01504074
• Other study ID #: 071/2009
• Status: Completed
• Phase: N/A
• First received: December 28, 2011
• Last updated: September 23, 2015
• Start date: November 2011

Study information

• Verified date: September 2015
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Federal Ministry for Health and Women
• Study type: Observational

Clinical Trial Summary

Purpose: To evaluate morphological and functional characteristics of Irvine Gass syndrome

Methods: 30 patients suffering on Cystoid macular edema (CME) secondary to Cataract surgery will be observed and evaluated by fluorescein-angiography, SD-OCT, reading performance, contrast sensitivity and microperimetry in a fixed time schedule

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• > 18 years

• St.p Cataract surgery

• able to read

• informed consent

• with fluorescein angiography and SD-OCT diagnosed Irvine Gass syndrome

Exclusion Criteria:

• < 18 years

• CME of other origin

• diabetic macular edema

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Irvine Gass Syndrome
• Macular Edema

Intervention

Behavioral:
• if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection
if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection

Locations

Country	Name	City	State
Austria	Department of Ophthalmology Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of central retinal thickness		3 months	No
Secondary	Increase of Best corrected visual acuity		3 months	No